|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
University Hospital, Brest |
|---|---|
| Information provided by: | University Hospital, Brest |
| ClinicalTrials.gov Identifier: | NCT00349661 |
Purpose
Objectives: A prospective investigation of the effect of omeprazole, a proton pump inhibitor, on the anti-platelet action of clopidogrel.
The main decision criterion will concern change in VASP protein phosphorylation under treatment. Phosphorylation will be measured before and after administration of omeprazole versus placebo in patients undergoing clopidogrel treatment.
Type of study: Single center, double blind, randomized parallel group study versus placebo, comparing two treatment groups:
Study population: 120 patients from the Cardiology Department of Brest University hospital, Brest (France), receiving a standard treatment comprising a loading dose of clopidogrel followed by a daily dose of 75 mg associated to 75 mg aspirin, will be randomized between 20 mg/day omeprazole and 20 mg/day placebo treatment groups. The efficacy of clopidogrel will be assessed by inter-group comparison on the VASP test.
Study period: 7 days' treatment per patient. Total study period estimated at 6 months.
Expected findings: The results should confirm the suspected negative effect of omeprazole on clopidogrel's impact on arterial thrombosis risk, secondarily allowing new recommendations to be drawn up for this association.
| Condition | Intervention | Phase |
|---|---|---|
|
Coronary Heart Disease |
Drug: impact on VASP test |
Phase III |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Pharmacokinetics Study |
| Official Title: | Influence Of Omeprazole On The Anti-Platelet Action Of Clopidogrel Associated To Aspirin: Double-Blind Randomized Trial Against Placebo |
| Estimated Enrollment: | 120 |
| Study Start Date: | June 2006 |
| Study Completion Date: | December 2006 |
Preventing recurrence of thrombosis following angioplasty relies on dual-therapy associating the anti-platelet agents aspirin and clopidogrel. This regime is kept up for between 1 and 6 months, depending on the type of stent deployed in the angioplasty. The biological effectiveness of the clopidogrel treatment can be assessed by the VASP test, a new platelet test, results on which have been shown to correlate with risk of thrombosis. A study we ran recently strongly suggested that omeprazole was associated with a poor response to clopidogrel. Omeprazole is an anti-ulcer agent frequently prescribed to prevent unwanted side-effects of aspirin, making it frequently associated to clopidogrel in the aftermath of angioplasty.
Study population: 120 patients from the Cardiology Department of Brest University hospital, Brest (France), receiving a standard treatment comprising a loading dose of clopidogrel followed by a daily dose of 75 mg associated to 75 mg aspirin, will be randomized between 20 mg/day omeprazole and 20 mg/day placebo treatment groups. The efficacy of clopidogrel will be assessed by inter-group comparison on the VASP test.
Study period: 7 days' treatment per patient. Total study period estimated at 6 months.
Eligibility| Ages Eligible for Study: | 18 Years to 85 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations More Information
| Study ID Numbers: | OCLA |
| Study First Received: | July 6, 2006 |
| Last Updated: | August 22, 2008 |
| ClinicalTrials.gov Identifier: | NCT00349661 |
| Health Authority: | France: Afssaps - French Health Products Safety Agency |
|
clopidogrel omeprazole |
|
Arterial Occlusive Diseases Coronary Disease Heart Diseases Aspirin Clopidogrel Myocardial Ischemia |
Vascular Diseases Omeprazole Arteriosclerosis Ischemia Coronary Artery Disease |
|
Molecular Mechanisms of Pharmacological Action Therapeutic Uses Hematologic Agents Anti-Ulcer Agents Gastrointestinal Agents |
Platelet Aggregation Inhibitors Enzyme Inhibitors Cardiovascular Diseases Pharmacologic Actions |
